Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Mallinckrodt
Johnson and Johnson
AstraZeneca
Dow
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,910,132

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 7,910,132 protect, and when does it expire?

Patent 7,910,132 protects ABSTRAL and is included in one NDA.

This patent has seventy-two patent family members in twenty-eight countries.

Summary for Patent: 7,910,132
Title:Pharmaceutical composition for the treatment of acute disorders
Abstract:A pharmaceutical composition for the treatment of acute disorders is described. The composition comprises an essentially water-free, ordered mixture of at least one pharmaceutically active agent in the form of microparticles which are adhered to the surfaces of carrier particles which are substantially larger than the particles of the active agent or agents, and are essentially water-soluble, in combination with the bioadhesion and/or mucoadhesion promoting agent. The invention also relates to a method for preparing the composition and to the use of the composition for the treatment of acute disorders.
Inventor(s): Pettersson; Anders (Kode, SE), Nystrom; Christer (Lidingo, SE)
Assignee: Orexo AB (Uppsala, SE)
Application Number:11/544,660
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 7,910,132

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-001 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-002 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-003 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-004 Jan 7, 2011 AB RX Yes Yes   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-005 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
Sentynl Theraps Inc ABSTRAL fentanyl citrate TABLET;SUBLINGUAL 022510-006 Jan 7, 2011 AB RX Yes No   Start Trial   Start Trial Y MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,910,132

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803240Sep 24, 1998

International Family Members for US Patent 7,910,132

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365540   Start Trial
Australia 6492799   Start Trial
Australia 764346   Start Trial
Bulgaria 105379   Start Trial
Bulgaria 65502   Start Trial
Brazil 9913945   Start Trial
Canada 2345121   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Johnson and Johnson
Medtronic
McKinsey
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.